“…4 We do not agree with the authors that the 2017 WHO system has been created without consideration of any additional biomarkers of potential prognostic value. 1 Several studies of biomarkers, cited in the article published in 2009, 3 supported the concept of the LC, which provides together with the amended LC the foundation of the morphological criteria for the 2017 WHO classification. None of them, including very recent molecular studies, 7,8 can replace morphological data as the leading guidance for clinicians in selecting appropriate treatment and evaluating the risk of progression.…”